← All trials
NCT04897503
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 16, 2021
- Primary completion
- Jun 30, 2023
- Completion date
- Dec 31, 2023
- First posted
- May 21, 2021
- Last posted
- Aug 24, 2021
- Enrollment
- 170
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Cornea and Laser Eye InstituteLead sponsor
- Hersh Vision GroupStudy director
- Hersh Vision GroupOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.